180 Life Sciences (NASDAQ:ATNF) Given "Sell (E+)" Rating at Weiss Ratings

Key Points

• 180 Life Sciences has received a "sell (e+)" rating from Weiss Ratings, indicating a continued negative outlook for the company's stock.
• The stock has declined by 28.9%, with a current market capitalization of $45.96 million and a P/E ratio of -0.50.
• Anson Funds Management LP has recently acquired a 7.08% stake in the company, purchasing 225,271 shares valued around $410,000.

180 Life Sciences (NASDAQ:ATNF - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by equities researchers at Weiss Ratings in a research report issued to clients and investors on Thursday,Weiss Ratings reports.

180 Life Sciences Stock Down 28.9%

ATNF opened at $7.61 on Thursday. The business has a fifty day moving average of $2.15 and a 200 day moving average of $1.46. The stock has a market cap of $45.96 million, a P/E ratio of -0.50 and a beta of 0.38. 180 Life Sciences has a 52-week low of $0.66 and a 52-week high of $17.75.

180 Life Sciences (NASDAQ:ATNF - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The company reported ($0.30) EPS for the quarter.

Institutional Trading of 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Anson Funds Management LP purchased a new stake in 180 Life Sciences Corp. (NASDAQ:ATNF - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 225,271 shares of the company's stock, valued at approximately $410,000. Anson Funds Management LP owned approximately 7.08% of 180 Life Sciences as of its most recent filing with the SEC. 4.07% of the stock is owned by institutional investors.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.